69/18/2818 16:38 Fron: HE 8 ootson C. Merrell M Webfax Page: 5/11 ee rere Patient: EPSTEIN, JEFFREY Specimen ID: 257-480-2371-0 DOB: 01/20/1953 Patient ID: Contret ID: 5831143092 Date collected: 09/14/2018 1255 Local Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. TSH 1.250 ulU/mL 0.450 - 4.500 01 Vitamin D, 25-Hydroxy 20.2 Low ng/mL 30.0 - 100.0 01 Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Bolick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30. Lipoprotein (a) 20 nmol/L <75 01 Note: Values greater than or equal to 75 nmol/L may indicate an independent risk factor for CHD, but must be evaluated with caution when applied to non~-Caucasian populations due to the influence of genetic factors on Lp(a) across ethnicities. IGr-1 Insulin-Like Growth Factor I 137 ng/mL 49 - 188 02 ANA w/Reflex ANA Direct Negative Negative 01 Homocyst(e)ine, Plasma 14.9 umol/L 0.0 - 15.0 01 Prolactin 3.9 Low ng/mL 4.0 - 15.2 01 Thyroxine (T4) Free, Direct, $s T4, Pree (Direct) 1.05 ng/dL 0.82 - 1.77 01 Cortisol 3.7 ug/dL 01 Cortisol AM 6.2 - 19.4 Cortisol PM 2.3 - 11.9 Date tssvect 09/18/18 1053 ET PRELIMINARY REPORT Page 4of 5 This document contains private and confidential heath information protected by state and federa! law. © 1995-2018 Laboratory Corporation of Amerka® Holdings you have received this document in error, please call 800-631-5250 All Rights Reserved - Enterprise Report Version: 1.00 EFTA00314041